Novo Nordisk A/S (ADR) (NYSE:NVO) Investor Lawsuit alleges Misleading Statements

An investor, who purchased shares of Novo Nordisk A/S (ADR) (NYSE:NVO), filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Novo Nordisk A/S.

Investors who purchased shares of Novo Nordisk A/S (ADR) (NYSE:NVO) have certain options and for certain investors are short and strict deadlines running. Deadline: March 13, 2017. NYSE:NVO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of Novo Nordisk A/S (ADR) (NYSE:NVO) common shares between April 30, 2015 to October 27, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 30, 2015 to October 27, 2016 Novo Nordisk A/S reported allegedly materially false and misleading earnings and forecasts in that they were inflated through the collusive price fixing of the Company’s insulin drugs.
The Complaint also alleges that Novo Nordisk A/S misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.

Those who purchased shares of Novo Nordisk A/S (ADR) (NYSE:NVO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com